Zinc L-carnosine in gastric ulcers: a profile of its use

2019-08-25T21:24:47Z (GMT) by Katherine A. Lyseng-Williamson

Compliance with ethical standards


Disclosure: The preparation of this review was not supported by any external funding.


Conflicts of interest: K.A. Lyseng-Williamson is an employee of Adis International Ltd./Springer Nature and is the Editor of Drugs & Therapy Perspectives and has no other conflicts of interest to declare. The Editor of D&TP was not involved in any publishing decisions for the manuscript.


Additional information about this Adis Drug Review can be found here


Abstract

Oral zinc L-carnosine (Gastrozin®) 75 mg twice daily is an effective gastric mucoprotective option for the treatment and prevention of gastric ulcers. The two components of the chelated compound (i.e. zinc and L-carnosine in a 1:1 ratio) provide beneficial anti-inflammatory, antioxidant and other effects that work together to support the natural mucoprotective mechanisms of the gastrointestinal tract. Zinc L-carnosine 75 mg twice daily has well established efficacy in the treatment of gastric ulcers, and is at least as effective as other mucoprotectants in this indication. It consistently provides rapid healing of gastric ulcers regardless of their underlying cause, such as gastritis, Helicobacter pylori infection and endoscopic submucosal dissection (ESD), or concurrent pharmacological treatment (e.g. H. pylori eradication or proton pump inhibitor therapy).

© Springer Nature Switzerland AG 2019